TY - JOUR T1 - Chronic thromboembolic pulmonary hypertension: the evolving treatment landscape JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW SP - 173 LP - 177 DO - 10.1183/16000617.00001515 VL - 24 IS - 136 AU - Nick H. Kim AU - Eckhard Mayer Y1 - 2015/06/01 UR - http://err.ersjournals.com/content/24/136/173.abstract N2 - Chronic thromboembolic pulmonary hypertension (CTEPH) is a unique form of pulmonary hypertension (PH) arising from the obstruction of pulmonary arterial vessels by organised thromboembolic material [1]. Much like other forms of PH, CTEPH has historically proven to be a challenging clinical entity in that it is frequently underdiagnosed and undertreated [1–3]. This lack of clinical recognition can result in patients with CTEPH experiencing progressive PH and eventual right ventricular failure [1, 4]. PEA is the treatment of choice for operable CTEPH. Riociguat is the first medical therapy for inoperable CTEPH http://ow.ly/LXTZ0 ER -